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ABSTRACT 
Bone metastases from tumours have a huge impact on the quality of life of millions of people 
around the world as treatment is still unsatisfactory.  The use of therapeutic 
radiopharmaceuticals for bone palliation is an important strategy in the management of 
metastatic bone cancer, since it can deliver radiation doses to specific areas affected by cancer 
cells, and thus play important role in providing better quality of life for patients with diffuse 
metastatic bone cancer. The carrier ligands capable of delivering the radioactive metal drug 
should have high binding affinity to avoid leaching before the target is reached and remains a 
challenge till today. 
This project aims to develop novel carrier ligands, constructed from quinoline, phosphine and 
phosphonate derivatives for enhanced chelation to selected lanthanide metals with desirable 
radiation properties to treat bone cancer. In this context, a multi-step route has been developed 
towards the synthesis of two novel chelators, namely 5depmqdep (5-((diethoxy phosphinyl) 
methyl) quinolin-8yl diethyl phosphate) and 5depmqdpp (5-((diethoxy phosphinyl) methyl) 
quinoline-8yl diphenyl-phosphinate. Additionally, 1-aminoethane-1,1-diyl diphosphonic acid 
was incorporated to enhance the adsorption of the compound to target bone sites. Due to the 
electron-rich nature of the phosphines, it was found to readily oxidize.    
Four complexes of samarium were synthesized, firstly with 5depmqdep and 5depmqdpp, and 
then another two complexes further enhanced with 1-aminoethane-1,1-diyl diphosphonic acid. 
The chemical structure of all the compounds synthesized (precursors, chelators and complexes) 
were confirmed by CHN elemental analysis and spectroscopic methods including FTIR, 1H, 
31P, 13 C NMR and high-resolution mass spectrometry.  
All compounds were tested for toxicity against HT-29 colon cells and showed good to excellent 
cell viability. A preliminary adsorption study of the metal complexes was performed on 
hydroxyapatite, which is the structural prototype of bone mineral. The results show complete 
adsorption of the samarium and a release of calcium from the mineral, showing that the 
complexes have potential as bone cancer palliative drugs.  
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CHAPTER I: LITERATURE REVIEW 
This chapter provides an overview of the global cancer burden and bone metastases. This is 
followed by a discussion on treatment methods currently available, and more in particular the 
use of lanthanide complexes as this constitutes the primary research approach of this study.   
1.1. Cancer  
Cancer is a worldwide major public health problem (more than HIV/AIDS, TB and malaria 
combined), which afflict all communities without exception (see Figure I-1) [1-3] 
 
Figure I-1:World map showing the spread of cancer. 
The increase of cancer cases worldwide presents a major health burden and compromises 
human well-being [4].  According to GLOBOCAN and the World Cancer Report 2014 there 
are a rapid increase in the number of new diagnosed cancer cases and cancer related deaths 
globally. In 2008 12.7 million new cancer cases and 7.6 million cancer related deaths were 
reported. These numbers increased in 2012 to 14.1 million new cancer cases and 8.7 million 
deaths, with a further increase in 2015 to 17.5 million and 8.7 million, respectively [2].  The 
incidence is predicted to rise to 19 million of new cases in 2025, 21.7 million new cases and 
13 million deaths in 2030, and 24 million new cases in 2035 [1,5] 
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The most frequently diagnosed cancers are lung (1.82 million), breast (1.67 million), and 
colorectal cancer (1.36 million), with the most common causes of cancer death attributed to 
lung (1.6 million deaths), liver (745,000 deaths), and stomach cancer (723,000 deaths) [6] . To 
a large extent the above could be linked to the embracing of certain lifestyle behaviours such 
as smoking, poor nutrition and physical inactivity [3,7,8].  As shown in Figure I-2, the 
incidence of cancer is therefore clear and will put further strain on economies, not only in 
economically less developed regions with already limited medical resources and lack of 
national plans to combat the disease, but even in countries with advanced health systems [9]. 
 
Figure I-2: Graph of estimated number of incidence and mortality worldwide 2012, for both 
sexes by level of economic development region [6]. 
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1.1.1. Secondary tumours 
The manifestation of cancer in a person and the non-treatment thereof could lead to malignant 
tumours from which cancerous cells can be released and carried around the body beyond where 
the tumour originated (see Figure I-3) to form secondary tumours called metastases [10,11]. 
Metastasis is a complex multistep process that involves loss of intercellular cohesion, cell 
migration and is in addition to genetic and external environmental factors, the physical 
interactions of cancer cells with their microenvironment, as well as their modulation by 
mechanical forces. Each of these may be key determinants of the metastatic process [12]. 
Each cancer, originating from a specific primary site, will lead to specific metastasis sites as 
illustrated in Figures I-3 and I-4 and also detailed in Table I-1. From this, it is clear that 
bone, liver, and lung are the most common sites where cancer can spread. 
 
Figure I-3: How cancer spread in the body[13]. 
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Figure I-4:  Main sites of metastases for some common cancer types [14]. 
Table I-1: Most common sites of metastasis for some common cancer [13]. 
Cancer type            Main sites of metastasis 
Bladder                       Bone, liver, lung 
Breast                         Bone, brain, liver, lung 
Colon                          Liver, lung, peritoneum 
Kidney                        Adrenal gland, bone, brain, liver, lung 
Lung                           Adrenal gland, bone, brain, liver, other lung 
Melanoma                  Bone, brain, liver, lung, skin, muscle 
Ovary                          Liver, lung, peritoneum  
Pancreas                    Liver, lung, peritoneum 
Prostate                      Adrenal gland, bone, liver, lung 
Rectal                         Liver, lung, peritoneum 
Stomach                     Liver, lung, peritoneum 
Thyroid                       Bone, liver, lung 
Uterus                        Bone, liver, lung, peritoneum, vagina 
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In particular, bone metastasis leads to painful and untreatable consequences causing a 
substantial increase in morbidity and mortality in cancer victims [10].  As the focus of this 
study is in particular on bone cancer, the next section details this topic.  
 
1.2. Bone metastasis 
Bone metastasis refers to the formation of metastases (secondary tumors) on the skeleton 
microenvironment [15]. As the skeleton is the supporting framework of the body and 
constitutes a large part thereof, it is a preferential site of metastasis resulting in the third most 
common site of metastatic disease after the lungs and liver. It is also known that the most 
common malignancy of bone is metastatic disease [16].  To create a specific lesion, tumour 
cells require interaction with the microenvironment of a specific host organ. This concept was 
first described in 1889 by Stephen Paget [17], when he noted that women with breast cancer 
had a greater probability to develop metastasis to bone than other organs [18].  He explained 
how certain cancers can only develop in specific organs.  Then he proposed that tumour cells 
acted as “seeds” and have affinity for specific microenvironment of select organs “soil”. Thus, 
metastases will develop only when the appropriate seed is implanted in its suitable soil [19].  
The understanding of the above interaction it is important to understand the mechanism of bone 
metastases and the microenvironment of bone, and although beyond the scope of this study, is 
explained here briefly. 
1.2.1. Mechanism of bone metastases 
The initiation of bone metastasis is a complex multistep process (see Figure I-5) which starts 
by carcinogenesis, the growth of a primary tumour, which spreads cancerous cells that then 
encounter the bone microenvironment. This is followed by new vessel formation promoted by 
the primary malignant neoplasm, angiogenesis and the invasion of cells into the circulation 
system (intravasation). The vascular system transports the cancer cells to capillary beds in 
bone. The aggregation of tumour cells and blood cells form embolisms which arrest in distant 
capillary beds in bone.  The cancer cells adhere into the vascular endothelial cells to escape the 
blood vessels (extravasation). Their adherence into the bone results in their exposure to 
microenvironment factors which promote growth of metastases [20].  
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Figure I-5: Main steps involved in tumour cells initiation, progression and bone 
metastasis[21]. 
This bone microenvironment includes osteoclasts, osteoblasts, osteocytes, endothelial cells and 
cells of the bone marrow. The continuous remodelling of the bone microenvironment exhibits 
a unique pathophysiology for occurrence of metastases (see Figure I-6 [18]). The “seed” and 
“soil” hypothesis tells us that the microenvironment provides a fertile ground (soil) for the 
survival and growth of the cancer cells (seeds). The bone formation and resorption will release 
and activate survival and growth promoting factors which may contribute to the development 
of bone metastases [19]. However, the bone microenvironment plays a critical role in regulating 
the growth of bone metastases. 
 
Figure I-6: Depiction of seed and soil hypothesis in bone metastasis  [18]. 
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The penetration of cancer cells into the bone results in the development of lesions. These 
lesions are commonly classified as osteolytic (in which bone is broken down), osteoblastic (in 
which bone is formed) or mixed, depending on the primary mechanism of interference with the 
normal bone remodelling and the different factors responsible [19]. 
 
1.2.2. Bone physiology and structure 
Bone tissue is a complex, variable and dynamic structure, comprising of protein and minerals 
coexisting in equilibrium, in which the osteocytes and vascular structures are suspended [22].  
It is a dynamic tissue that maintains the mineral balance in an organism, as well as providing 
an environment for cellular machinery involved in different physiological functions [23]. As 
shown in Figure I-7, bone tissue is organised into cancellous or cortical bone. Cancellous bone 
is porous, providing structural support and organisation for bone marrow interspersed on its 
internal cavity, while cortical bone is the compact bone surrounding the marrow space, and 
confers mechanical strength to bone. The outer layer that covers the surface of cortical bones 
is the periosteum, containing mainly blood vessels and osteoblasts, which are activated during 
appositional growth and bone repair [24]. Within the osteon exist osteoblasts and the mature 
osteocytes, which contribute to the generation and maintenance of the Extracellular Matrix 
(ECM) that gives bone its structural strength [10]. 
 
Figure  I-7. Schematic overview of bone, depicting gross overview and cellular 
distribution[24]. 
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The ECM in the bone is highly mineralised and contributes to approximately 70% of bone 
mass. Calcium and phosphate ions are found in the form of hydroxyapatite crystals with 
formula Ca5(PO4)3OH, crystallised in a hexagonal lattice and stacked in a plate-like fashion 
with two distinct calcium environments, one being seven coordinated and the other nine 
coordinated (see Figure I-8 [25]). 
 
Figure I-8: The structure of hydroxyapatite viewed along c-axis [25]. 
The crystals of bone apatite have a highly reactive surface where either Ca2+or PO4
3– ions are 
exposed and can undergo complete replacement of some of its ions without changing 
structures, e.g. the replacement of OH–   with F– leads to the formation of fluorapatite [25-27]. 
1.2.3. Epidemiology of bone metastasis 
Most carcinomas especially of the breast, lung, prostate, kidney, and thyroid frequently 
metastasize to the bone, inducing pain [28-29]. The prevalence of painful osseous metastases 
varies among different types of cancer: approximately 65% of patients with prostate or breast 
cancer and 35% of those with advanced cancers of the lung, thyroid, and kidney develop 
symptomatic skeletal metastases (Table I-2) [30-32] 
However, bone metastases may complicate a wide range of malignancies, resulting in 
considerable morbidity and complex demands on health care resources [33]. 
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Table I-2: Incidence of bone metastases in different cancers [30].  
Primary Tumour               Incidence of bone metastases (%) 
Breast                                                              75 
Prostate                                                           68 
Thyroid                                                            42 
Lung                                                                36 
Kidney                                                             35 
Gastrointestinal tract                                         5 
The most common site of bone metastasis is the spine. Other common sites identified are the 
hip bone (pelvis), upper leg bone (femur), upper arm bone (humerus), ribs and skull [34]. 
  
1.2.4. Signs and symptoms of bone metastases 
Bone metastasis is major cause for morbidity [19] characterised by major clinical problems 
among of which the most common include severe pain, fracture, spinal cord compression and 
a high calcium blood level [32,35], all of which compromises the patient’s quality of life [36]. 
1.3. Bone metastases therapies 
Cancer that has spread to the bone becomes difficult to treat due to the invasion and release of 
tumour cells in the circulation system. The heterogeneity of the primary cancer also leads to 
difficulties in identifying the different factors that are predictive of metastases and potential 
targets for therapy [42]. Furthermore, the mechanism of the molecular interaction within the 
bone microenvironment is not well understood. The above remains a major challenge to find 
the best therapeutic agents to block metastasis to bone. Currently palliative treatment of 
patients with bone involvement aims primarily to minimize pain and other clinical symptoms 
resulting in a better quality of life of a patient with bone metastasis [18]. However, a shift is 
required from palliative care to more specific and effective treatments for bone metastases [15]. 
Depending on the extent and location of cancer cells two types of palliative treatment for bone 
metastases are identified: local treatments and systemic. In general, local treatments are used 
on single areas when cancer cells have spread to only one bone. This treatment includes: 
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External radiation therapy: Radiation therapy can be used in the management of bone 
metastases for both local and widespread pain and is effective for spinal canal suppression and 
pathological fracture where it may also have a prophylactic role [37]. 
Surgery: Surgery can be applied to treat bone metastases to relieve symptoms by stabilizing 
bone to prevent fractures. An operation can be performed to insert screw, rods, plates, pins or 
other devices to make the bone more stable [13]. 
 
Systemic treatment is used to affect all of the body, especially when cancer cells have spread 
to several bones in the body. This treatment includes: 
Chemotherapy: Chemotherapy (chemo) uses anti-cancer drugs taken by mouth or injected 
into the vein to kill cancer. Drugs enter the bloodstream and circulate in the body. It is used as 
main treatment for many types of metastasis cancer [13]. 
Hormone therapy: Hormone therapy drugs are used to block the action of certain hormones 
by interrupting   cell growth and causing tumours to shrink. This therapy is mostly used for 
breast and prostate cancer and when these cancer cells have spread to the bone [34].  
Targeted therapy: Targeted therapy drugs attack a specific area of cancer cells and even the 
protein that contributes to cancer cell growth. This treatment can be used alone or combined 
with other treatments such as chemo and hormone therapy [34]. 
Immunotherapy: Immunotherapy boosts the body’s immune system or utilise man-made 
versions of immune system proteins to destroy cancer cells. This treatment may also be used 
to manage bone metastases [13]. 
Denosumab: Denosumab keeps osteoclasts from being turned on by blocking RANKL. This 
drug is used when cancer has spread to bone [13]. 
Bisphosphonates: Bisphosphonate drugs help to prevent bone damage caused by tumours. 
When reached targeting region of high bone turnover with elevated osteoclast, effectively 
disrupting osteoclast function and hence, bone resorption [38] 
Radiopharmaceuticals: Radiopharmaceuticals are a group of drugs that carry radioactive 
elements [34].  These drugs are injected into the vein and spread to a part of bone with 
metastases; once there, they kill cancer cells by the radiation they emit [13]. 
 
A summary of recommended guidelines on the treatment of bone metastasis from the individual 
2017 National Comprehensive Cancer Network (NCCN) is presented in Table I-3.  Cancers 
with the highest bone metastases treatment prevalence were selected. 
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Table I-3. Treatment options for various types of bone metastatic cancers [18]. 
 Prostate Breast Renal Lung Thyroid Multiple 
Myeloma 
Systemic 
therapy 
Yes Yes Yes Yes Yes Yes 
 
Bone-
Targeted 
 
Denosumab 
 
Denosumab 
 
Denosumab 
 
Denosumab 
 
Denosumab 
 
Pamidronate 
Zoledronic 
Acid 
Zoledronic 
Acid 
Zoledronic 
Acid 
Zoledronic 
 Acid 
Pamidronate Zoledronic 
Acid 
Radium-223 Pamidronate   Zoledronic 
acid 
 
Radiation 
therapy 
Yes Yes Yes Yes Yes Yes 
 
Vitamins 
 
Calcium 
Vitamin D 
 
Calcium  
Vitamin D 
 
Calcium  
Vitamin D 
 
Not 
mentioned 
 
Not 
mentioned. 
 
Not 
mentioned 
 
Notes 
Possible use 
of Sr-89 or 
Sm-153 
   Consider 
embolization 
prior to 
surgical 
resection to 
reduce 
hemorrhage 
 
 
As the focus of this study was in particular on radiopharmaceutical treatment, the following 
sections detail this area of research. 
 
1.4. Radiopharmaceutical treatment of bone metastasis. 
1.4.1. General considerations for therapy 
Radiopharmaceuticals are drugs that contain radioactive elements, and when administered, 
may radiate and kill cancerous cells [34]. The disadvantage is that healthy cells are not spared 
and therefore a primary requirement is that the radio-element be guided for targeted delivery 
to the cancer site. Thus the primary strategy is to develop a drug with high selectivity to cancer 
cells that will help to minimise dose and toxic side effects [39].  
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The most common method is to use a chelator that captures the radio-element strongly enough 
not to be released in vivo. Chelators are an important part of radiopharmaceuticals and have 
received a lot of research interest. The choice of the chelator depends on the physical and 
chemical properties of the metal ions, the coordination chemistry, complexation reaction of the 
metal ion and the chemistry for the introduction of the chelator into the biologically active 
compound [40].  A large number of polydentate chelators have been developed and some 
examples of selective binding units are shown in the Figure I-9.  
The chelator, itself or further functionalised, should also be capable of guiding the metal to the 
specific target site [41]. Targeting is usually achieved by grafting biologically active targeting 
molecules onto the chelator [42]. In the case of bone cancer/metastasis the high concentration 
of minerals present in bone and pathological calcifications are unique compared to all other 
tissues and thus provides an opportunity for targeted delivery of pharmaceutical drugs [43]. 
This feature, together with the use of strong coordinating chelators, minimises the exposure of 
healthy tissue to radiation.  
To summarise the above description, Figure I-10 presents in a cartoon style the principles for 
design of a radiopharmaceutical targeted drug for the treatment of bone metastases.  
 
Figure  I-9. Selective bonding units for building polydentate chelators, adapted from [40,41] 
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Figure I-10. Radiopharmaceutical design targeted drug delivery to bone tissue [42]. 
The use of therapeutic radiopharmaceuticals for bone palliation is an important strategy in the 
management of metastatic bone cancer since they can deliver radiation doses to specific bones 
affected by cancer cells. They also play an important role in providing a better quality of life 
for patients with diffuse metastatic bone cancer [44]. It is important that the emitted particles 
should have an energy and tissue penetration range compatible with the volume of the lesion 
while minimising the dose to healthy bone sites and adjacent tissues [32]. Table I-4 summarises 
the properties of some radio-elements that meet these requirements and are used in bone cancer 
treatment. 
Table I-4: Physical and nuclear characteristics of selected bone-seeking therapeutic 
radionuclides [45]. 
Element 
Maximum β- 
Energy(MeV) 
Average β- 
Energy(MeV) 
Average  
Range (mm) 
t1/2 
(days) 
γ photon 
(MeV) 
Strontium-89 1.46 0.58 2.4 50.5 None 
Phosphorus-32 
Tin-117m 
 
Erbium-169 
Lutetium-177   
Rhenium-186 
Samarium-153 
Holmnium-166    
Rhenium-188                
1.71 0.70 3.0 14.3 None 
0.132 
0.152 
0.34 
0.50     
1.08  
0.81 
1.84   
2.12                         
_ 
_ 
0.11 
0.14 
0.33 
0.22 
0.67 
0.64 
0.22 
0.29 
0.30 
0.35 
1.05 
0.55 
3.3 
3.8 
14.0 
 
9.3 
6.7 
3.7 
1.9 
1.1 
0.71 
0.159(86%) 
 
None 
0.208(11%) 
0.137(9%) 
0.103(29%) 
0.081(6%) 
0.155(10%) 
1Arranged in order of decreasing half-life, 2Conversion electrons with discrete energies (and range) 
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Some of the radio-elements have been approved for use in the USA include: Strontium-89 
(Matastron®), Samarium-153 (Quadramet®) and Radium-223 (Xofigo®) [13]. Elements from 
the lanthanide1 series (Ln) have also received attention for their used as metal 
radiopharmaceuticals. For the current study we have focussed on these, and therefore it is 
discussed in more detail in the next section. 
1.4.2. Suitability of lanthanides for bone therapy 
Lanthanides have the potential to exchange with calcium in bone and affect the bone 
remodelling cycle by modulating osteoblast and osteoclast development. The affinity of 
lanthanides for bone can be explained by their chemical and biological similarities to calcium 
(summarised in Table I-5) and as a result have stimulated research into their therapeutic 
application for bone palliation [25,31,46-48] 
Table I-5. Salient features of lanthanide and calcium [49]. 
Property Ca2+ Ln3+ 
Coordination number  6-12 reported 6-12 reported 
Coordination geometry 6 or 7 favoured 8 or 9 favoured 
Donor atom preference O>>N>>S O>>N>>S 
Ionic radius (Å) 1.00 -1.18 (CN 6-9) 0.86 -1.22 (CN 6-9) 
Type of bonding Ionic Ionic 
Hydration number 6 8 or 9 
Water exchange rate constant (S-1) ~5x 108 ~5x 107 
Diffusion coefficient (cm2/s x105)    1.34 1.30 
Crystal Field stabilisation None Negligible 
Lanthanides have an exceptionally high affinity for bone tissue that is attributed to their 
preference for hard donor ligands and coordination numbers ranging from 7 to 10. Studies have 
shown that they are highly suited for substitution into a hydroxyapatite (HAP) phosphate-rich 
matrix, a naturally occurring calcium phosphate with the formula [Ca5(PO4)3OH]n, that closely 
resembles biological bone mineral [25,28,50]. 
                                                          
1 Although IUPAC recently recommended the use of “lanthanoid”, the use of “lanthanide” is still accepted due 
to its wide use in literature, and therefore adapted in this work. 
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Several radioactive isotopes of lanthanides have appropriate radiation properties and half-lives 
(emitting a wide range of beta energies) and have been explored for therapeutic and bone pain 
palliation application (summarised in Table I-6) [41,50]. Thus, radiolanthanides continue to be 
of interest for the radiolabelling of a variety of therapeutic agents for applications in nuclear 
medicine, oncology and interventional cardiology [25,50]. 
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Table I-6: Lanthanide radioisotopes relevant for radiopharmaceutical chemistry and nuclear 
medicine [50]. 
Radionuclide T1/2 Main emission(e) Production route Application 
143Pr 13.58 d γ, β- (315 Kev) 142Ce(n, γ) →  β-,f Therapy 
147Nd 10.98 d γ, β- (233 Kev) 146Nd(n, γ);f Therapy 
149Pm 2.212 d β- (366 Kev) 148Nn(n, γ)→ β- Therapy 
153Sm 1.946 d γ, β- (225 Kev) 152Sm(n, γ) Therapy 
149Gd 9.2 d γ, ae, (3018 Kev) sp;147Sm(α, 2n) Therapy 
149Tb 4.16 h γ,α(3966Kev,16.7% sp;152Gd(p,4n),141Pr(12C,4n)  Therapy 
152Tb 17.5 h ae, γ sp;152Gd(p,n)                     Therapy 
161Tb 6.91d γ, β- (155 Kev) 160Gd(n, γ) → β- Therapy 
157Dy 8.1 h ae, γ sp;154Gd(α,n),159Tb(p,3n) Imaging 
165Dy 2.33 h γ, β- (442 Kev) 164Dy(n, γ)             Therapy 
166Dy 3.40 d γ, β- (119 Kev) 164Dy(n, γ)165Dy(n,γ)166Dy              Therapy 
161Ho 2.48 h ae (32 Kev), γ sp;159Tb(α,2n) Therapy 
166Ho 1.117 d β- (711 Kev) generator 166Dy Therapy 
160Er 1.192 d ae (6,5 Kev), γ sp Therapy 
165Er 10.36 h ae (6,6 Kev) 165Ho(p, n)             Therapy 
169Er 9.4d β- (99.6 Kev) 168Er(n, γ)             Therapy 
171Er 7.52 h β- (359 Kev) 170Er(n, γ)             Therapy 
167Tm 9.24 d γ, ae sp;165Ho(α,2n) Imaging&Ther. 
166Yb 2.362 d γ, ae(38.9 KeV) sp;169Tm(p,4n)                  Therapy 
175Yb 4.19 d γ, β- (127 Kev) 174Yb (n, γ)                  Therapy 
178Lu 6.71 d γ, β- (133 Kev) 176Lu(n,γ);176Yb(n,γ) → β- Therapy 
 
1.4.3. Bone targeting ability of bisphosphonates                                    
Bisphosphonates or diphosphonic acids are effective antiosteoporotic agents that are known to 
bind irreversibly to bone (see Figure I-11 as example) [43].  
 
Figure I-11: Schematic representations of two pamidronate’s binding site of bone [43]. 
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The literature reveals that the inclusion of bisphosphonate in known cancer drugs exhibited 
increased anti-tumour activity compared to those without (see Table I-7). The incorporation of 
a bisphosphonate functional group into the design of radiopharmaceuticals assists the drug to 
target bone. Chelators containing phosphonate groups complexed to radiolanthanides have 
already proven their efficacy as bone targeting agents [28,51]. 
Table I-7:  Antitumor agent conjugated to BP for the treatment of bone cancers [43]. 
Drug Summary of results 
Cisplatin Anti-tumour activity was greater than the non-targeted drug in vivo. 
Taxanes A high binding affinity was exhibited to hydroxyapatite in vitro and bone tumours in vivo. 
Anti-tumor activity was greater than the non-targeted drug and free BPs, in vitro and in vivo. 
Camptothecin A high binding affinity to hydroxyapatite was exhibited in vitro. 
Gemcitabine A high binding affinity was exhibited to hydroxyapatite in vitro and bone in vivo. 
Anti-tumour activity was greater than the free drug and control groups in vivo. 
Doxorubicin A high binding affinity to hydroxyapatite was exhibited in vitro. 
Methotrexate A high binding affinity to bone was exhibited in vivo. 
Proteasome 
inhibitors 
Binding to hydroxyapatite was greater than the non-targeted drug in vitro and in vivo. 
Anti-tumour activity was greater than the non-targeted drug, in vitro and in vivo, leading to 
increased overall survival of mice. 
Arabinocytidine The incidence of bone metastases and overall tumor burden was decreased in mice compared 
with no drug or zoledronate at the same dose. 
TNP-470 Anti-tumour activity was greater and cytotoxicity lower than the non-targeted drug or 
alendronate in vivo. 
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1.5. Aim and objectives of study 
 
The summary of the literature on bone cancer and treatment thereof, in particular the use of 
radiopharmaceutical drugs, has highlighted an ongoing need for the development of ligands, 
chelators, for the production of radiopharmaceuticals. The main aim of this project was to 
follow similar design principles mentioned, i.e. to develop novel chelators, selecting a suitable 
metal, incorporation of phosphonate moieties, followed by preliminary assessment of their 
effectiveness for bone pain palliation. To achieve this design outline, the following objectives 
have been identified: 
i. Synthesis of chelators based on quinoline. 
With several accessible sites on the quinoline backbone, it has potential to be developed 
as a chelator. Previous studies have shown 8-hydroxyquinoline to be a viable system 
[52], but derivatisation and the chelation ability of these as radiopharmaceuticals have 
not been fully explored.   
ii. Complexation of novel quinoline-based chelators to a selected lanthanide.  
It is clear that within the lanthanide series there are elements useful for bone therapy as 
they have radionuclides with nuclear decay parameters suitable for such application. 
Their close resemblance to calcium in terms of ionic radius, a strong affinity for bone, 
and high coordination numbers are some of the desirable characteristics mentioned.   
iii. Introduce phosphonate moieties, either before or after complexation. 
The literature reveals that the inclusion of bisphosphonate in known cancer drugs 
increased their anti-tumour activity compare to those without and that they display a 
strong affinity for binding to the bone.  
iv. Complete characterisation of chelators and complexes thereof. 
All materials prepared in this study will be characterised with all the necessary 
analytical techniques.  
v. Evaluate toxicity and the affinity for bone mineral. 
The prepared materials will be evaluated for toxicity using H-29 colon cells and for 
their bone adsorption with an in vitro HAP model to set the stage for possible in vivo 
studies for viable candidates. 
  
 19 
 
CHAPTER II: 8-HYDROXYQUINOLINE FUNCTIONALIZED   
PHOSPHONONATE LIGANDS: SYNTHESIS AND 
CHARACTERIZATION. 
2.1. Chapter outline. 
This chapter provides a brief introduction to 8-hydroxyquinoline and phosphonate moieties, 
followed by the synthesis and characterization of chelators based on these compounds. 
2.2. Introduction. 
The use of chelators for radionuclide anti-cancer drug delivery to the target organ has received 
a lot of research interest. The choice of the chelator depends on the chemical and physical 
properties of the metal ion, e.g. its coordination chemistry and solubility under physiological 
conditions [40]. The design strategy to develop a chelator includes tailoring it for high 
selectiveness towards cancer cells, negligible leaching of the radio metal, while keeping dosage 
and toxicity to a minimum [39]. Therefore, the synthesis of novel chelators improving on these 
desirable features is a necessity. 
Nitrogen-heterocyclic compounds are a family of chelators that are widely used in 
radiopharmaceuticals, and it is specifically here that our research focus is directed towards 
functionalised 8-hydroxyquinoline systems. Compounds containing the 8-hydroxyquinoline 
moiety have a range of chemical and physical properties that have shown versatility in various 
applications (see Figure II-1) [53].  
8-Hydroxyquinoline is desirable as a chelator in radiopharmaceutical drugs as it is lipophilic 
[54] and regarded as a strong metal ion chelator. Thus it represents an excellent scaffold with 
a wide spectrum of pharmacological and biological activities including anticancer, anti-HIV, 
antimicrobial, antidiabetic, anti-neurodegenerative, anti-inflammatory, anti-oxidant, iron-
chelators for neuroprotection and chelators of metalloproteins [54-57]. 
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Figure II-1: Examples of 8-hydroxyquinoline derivatives with applications in the areas of 
medical, OLEDs, agriculture, chemosensors, and metal extraction [57]. 
It is well known that the inclusion of phosphonates and/or organophosphorus moieties into the 
design of a pharmaceutical compounds afford enhanced pharmacological and biological 
activities [58,59], e.g.  diphosphonylation of quinolines leads to 
diphosphonotetrahydroquinolines, and some phosphorated derivatives of fluoroquinolines 
(ciprofloxacin, norfloxacin and sparfloxacin) show greater biological activities than the 
original drugs. As additional examples, the series of quinoline organophosphorus derivatives 
presented in Figure II-2 are known to have antibacterial (7) [60] and antiproliferation (3)[58,61] 
activities. Some of the other compounds shown in Figure II-2 have also been explored for their 
redox properties (2, 4, 5) [62,63], and metal chelating ability (1, 6) [64]. 
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Figure  II-2. Examples of quinoline organophosphorus derivatives. 
The combination of a soft Lewis P-donor site with a hard Lewis N-donor site represents a very 
distinguished family of hemilabile ligands (see Figure II-3) of importance in organometallic 
chemistry due to their wide application in chemistry industry and material science [65]. The 
reason for their good performance is twofold: firstly, steric factors, and then also the electronic 
asymmetry induced by the presence of significantly different donor atoms. 
 
Figure  II-3: Description of a polyfunctional hemilabile ligand system. 
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These multi-dentate ligands can stabilize metal ions in a variety of oxidation states and 
geometry (see Figure II-4),  and have been successfully utilized in asymmetric catalytic 
reactions such as allylic substitution [66], hydrosilylation, hydroformylation [67], 
hydroboration of olefins, ethylene oligomerization [65,68] and hydrogen transfer on ketones. 
 
Figure II-4: Examples of metal complexes with P, N ligand systems containing the 8-
hydroxyquinoline moiety. 
Furthermore, the coordination sites bearing hard atoms are weakly coordinated to soft metal 
centres (or vice versa) and can be easily dissociated in solution, affording a vacant site 
whenever demanded, whereas the chelate effect confers stability to the catalyst precursor in the 
absence of substrate. In addition, the introduction of an unsymmetrical P, N ligand into 
organometallic complex is expected to give higher selectivity and activity, because of a 
preferential vacant coordination site on metal centre [69]. 
From the brief overview provided into quinoline organophosphorus systems, it seems plausible 
that these systems may prove to be a potential alternative for bone cancer metal drug delivery: 
8-hydroxyquinoline has proven physiological activity, and when combined with phosphorus 
containing moieties, it may yield tuneable metal coordination stability, water solubility, as well 
as bone-seeking abilities. The initial objective of this study was to synthesize quinoline 
organophosphorus (III) derivatives with P, N donor atoms, but after several attempts it was 
found that the phosphorus center oxidizes to the +5 oxidation state. It was decided to continue 
with the oxidized phosphorus(V) center as the oxygen should in fact afford more stable bonds 
to the lanthanide series of elements [15] and thus minimize metal leaching. It is also believed 
that the possibility to vary substituents on phosphorus atom will influence electronic and steric 
properties and indirectly tailor the coordination environment of the O donor atom. 
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The design, synthesis and characterization of two novel organophosphorus derivative chelators 
bearing quinoline functionalised phosphonate moiety are detailed here. 
2.3. Experimental Methodology. 
All manipulations involving the synthesis of the precursor, ligands were carried out under inert 
dry nitrogen atmosphere by using standard Schlenk line techniques [68,70].  
2.3.1. Materials.  
8-hydroxyquinoline, diethyl-chlorophosphite, chlorodiphenylphosphine, triethyl phosphite 
were obtained commercially (Sigma-Aldrich) and used without further purification. Analytical 
grade solvents toluene, acetonitrile, diethyl ether and hexane were obtained from Rochelle 
chemicals and were dried using molecular sieve (3Å) overnight, filtered and then used 
immediately.  Triethyl amine was dried over sodium wire overnight and then distilled over 
fresh sodium wire.  
2.3.2.  Characterization techniques. 
The 1H, 31P{1H} and 13C{1H} NMR spectra were recorded on a Bruker 400MHz spectrometer 
All samples were dissolved in D2O as solvent.  IR spectra were recorded using a Perkin-Elmer 
BX FT-IR spectrophotometer in the frequency range of 4000 – 400 cm-1. Elemental analysis 
(C, H and N) was carried out using a Flash 2000 multi-analyser. Mass analysis of the products 
was performed by  high resolution electrospray ionisation time-of-flight mass spectrometry 
using a Waters Synapt G2, ESI probe injected into a stream of acetonitrile, ESI positive, Cone 
Voltage 15 V. Detailed synthesis and all the analytical data obtained are provided in 
Appendices A1 to C.  
2.3.3. Experimental methods overview. 
Scheme II.1 shows the synthetic route followed for the synthesis of the proposed quinoline 
organophosphorus compounds to be used as ligand systems later on. Initially 8-
hydroxyquinoline was functionalised at position 5 by introducing chloromethyl substituent 
which resulted in compound 2, then facilitates the addition of phosphite to produce 5-diethyl 
phosphanomethyl-8-hydroxyquinoline 3.   Hereafter the hydroxyl functionality at position 8 of 
the quinoline is converted to a phosphinite compounds 4 and 5.  
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Scheme II-1: General synthetic procedure for the synthesis of two quinoline phosphonyl 
compounds to be used for complexation. 
2.4. Results and Discussion 
The chelating ligands (L= 4 and 5) were prepared in three steps from 8-hydroxyquinoline 
following the pathway summarised in  Scheme II-1. The precursor 5-chloromethyl-8-
hydroxyquinoline 2 was prepared using a known method [71] the process involves 
chloromethylation of 1 at position 5 using CH2O, HCl and dry HCl gas to afford 2 [72]. 
Conversion of 2 into phosphonate 3 was readily accomplished by the Arbuzov reaction using 
P(OEt3)3 [36].  Derivatisation to the phosphonate-phosphate-substituted target ligands 4 and 5 
was accomplished   reaction of 3 with  diethyl-chlorophosphine and diphenyl chlorophosphine, 
respectively, to incorporate the phosphine moieties. The phosphorus center at this position was 
oxidised to form the P=O bond. 
 
The composition of 2 to 5 are supported by various characterisation techniques that include 
multi-nuclear NMR, FTIR, CHN-elemental and HRMS analysis. Additionally, the molecular 
structure of 3 is confirmed by single crystal X-ray diffraction analysis (Figure II-6). 
i) HCHO, HCl, HCl gas, r.t, 6h.   
ii) P(OEt)3, reflux,12h. 
iii) Toluene, NEt3, (C2H5O)2PCl r.t, 24h.  
iv) Toluene, NEt3, (C6H5)2PCl, r.t, 24h.  
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The IR, 1H NMR, 31C NMR and HRMS of compounds 2 and 3 closely match those from the 
literature. The detailed syntheses and all characterization data/spectra of 2 to 5 are provided in 
the Appendices A1-4, B1-9, C1-3, D1 and E.  Solubility test performed for all compounds has 
shown water to be the best solvent and thus also used for the collection of NMR data (as D2O). 
Table II-1 show the comparative characteristics 1H and/or 31P NMR peaks for the precursor 3 
and the ligands 4 and 5. 
 
Table II-1: Summary of NMR data (in D2O) for the synthesised chelators and their precursor 
                 
C
o
m
p
o
u
n
d
 
Quinolinic fragment 
 
 
Chloro 
methyl 
 
 
Diethoxy-phosphinylmethyl 
 
Diethyl-phosphate 
 
Diphenyl-phosphinyl 
 
 H2(d) H3(d) H4(dd) H6(dd) H7(d) CH2Cl(s) OCH2(q) CH2P(d) CH3(t)  P(s) OCH2(q) CH3(t)  P(s)  o  m  p  P 
2 9.09.  8.83 7.92 7.56 7.22 4.89  - - -  - - - - - - - - 
3 
4 
   5 
8.62  8.24 7.42 7.20 6.96  - 3.82  3.45 0.99 29.3 - - - - - - - 
8.63  8.20 7.39 7.31 7.18  - 3.74  3.38 0.99 27.6 4.06 1.06 -5.6 - - - - 
8.80 8.72 7.75 7.39 7.14  - 3.85  3.53 0.99 28.1 - - - 7.48 7.25 7.21 23.3 
d: doublet; dd: doublet of doublet; t: triplet; q: quadruplet; o: ortho, m: meta, p: para 
 
The 1H NMR spectra of (2, 3, 4, 5) acquired in D2O exhibited all the characteristic signals of 
the protons present. In 2, the singlet observed at 4.89 ppm (integrating as 2) is attributed to the 
two protons of the methylene linking bridge to quinoline 1 in 5 position, and the chemical shifts 
observed at 9.09, 8.83, 7.92, 7.56 and 7.22 ppm are assigned to the characteristic peaks of the 
five protons in the quinoline ring. For compound 3, the characteristic peaks of the triplet at 0.99 
ppm and quadruplet 3.82 ppm, integrating to 6 and 4 protons respectively, are assigned for 
diethoxy-phosphinyl on position 5 of quinoline, the doublet observed at 3.45 ppm split into 2 
singlets (integrating to 2) are assigned to the two protons of methylene (-CH2-) linking bridge 
to quinoline which shifted upfield as compared in 2. All the characteristic peaks of quinoline 
shifted up field to 8.62, 8.34, 7.42, 7.20 and 6.96 in 3. The spectrum of compound 4 and 5 
contain all the peaks observed in 3 with extra peaks observed at 1.06 ppm (triplet) and 4.06 
ppm (quadruplet) integrating to six and four protons that are characteristic of diethyl-phosphate 
for 4, while a multiplet is observed at ca. 7.48-7.21 ppm assigned to the characteristics 
absorption peaks of the 10 protons of aromatic rings in diphenylphosphinyl bonded to quinoline 
in position 8 for 5.  In summary, the 1H NMR of precursor 3 displays characteristic peaks for 
quinolinyl and diethoxy-phosphonylmethyl (5-P=O) fragments, and noticeable shifts of these 
values are observed with the introduction of the second phosphorus center (8-P=O) 
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diethylphosphate and Diphenyl-phosphinyl, the latter also showing significant shifts in 31P 
NMR values due to the electronic differences introduced by the substituents. 
From the FTIR spectra assignments can also be made to characteristic peaks, in particular those 
from the phosphorus environment (see Figure II-5).  
 
The high-resolution mass spectra (ESI-TOF-HRMS) of all compounds are consistent with their 
simulated HRMS. The peaks [M+H]+ was observed for the precursor 3, the ligands 4 and 5. 
Thus for 3 a peak observed at 296.1051 correspond to the m/z ratios of the molecule ion 
[M+H]+. The spectrum of 4 shows two main peaks, one observed at m/z 432.1341, 
corresponding to [M+H]+ and the other m/z 296.1051 can be assigned to [M-(C2H5O)2PO]
+ 
which  correspond to the precursor 3 fragment. The spectrum of 5 also show two prominent 
peaks. The peak observed at m/z 496.1437 corresponds to the [M+H]+, and the one observed  
at m/z 296.1046  correspond to the fragment of 3. 
 
 
Figure II-5: Superimposed FTIR spectra of (3), (4) and (5). 
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Figure II-6. Crystal structure of (3). 
 
 
2.5. Conclusion. 
The synthesis of two novel water soluble 5-(diethoxy) phosphinylmethyl-8-quinolinoxy 
phosphate derivatives 4 and 5 proceeded successfully through the reaction of 3 with diethyl 
chlorophosphite and chlorodiphenylphosphine respectively to incorporate the phosphate 
moieties. Each compound in the multi-step synthesis could be isolated, and various 
characterization techniques (NMR, IR, HRMS, CHN-elemental analysis and single crystal X-
ray crystallography) could be employed to ascertain successful overall synthesis. Although the 
phosphorus center of compounds 4 and 5 at position 8 readily oxidized, coordination to the 
metal center will still be feasible through the oxygen, and it was decided to pursue this avenue 
of the project, i.e. the coordination of these ligands with samarium, the biological activities of 
the materials and their adsorption on hydroxyapatite as model study for bone cancer agents. 
    
 
.
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CHAPTER III: LANTHANIDE COMPLEXES OF 5-(DIETHOXY) 
PHOSPHINYLMETHYL-8-QUINOLINOXY 
PHOSPHINE DERIVATIVES: SYNTHESIS AND 
CHARACTERIZATION. 
3.1. Chapter outline. 
The lanthanide elements are introduced, in particular those with radio-pharmaceutical abilities. 
The complexation of the 5-(diethoxy) phosphinylmethyl-8-quinolinoxy phosphine derivatives 
previously prepared are detailed.  
3.2. Coordination chemistry of lanthanide elements and their 
therapeutic relevance. 
The lanthanide elements are the group of 15 f-block elements from lanthanum to lutetium. 
When scandium and yttrium are included, this group of 17 elements are referred to as the rare 
earth elements, a name coined due to these elements’ high dispersity through the Earth’s crust.  
The lanthanide valence electron configurations are confined to the 4f-, 5d- and 6s-orbitals with 
ion formation primarily resulting in the +3-oxidation state with an electronic configuration of 
[Xe]4f n, where n = 0 to 14 across the lanthanide series starting from La (n=0) to Lu (n=14). As 
the f-electrons are buried more deeply in the underlying electron shells, these elements exhibit 
a decrease in atomic size and radius with increasing atomic number, known as lanthanide 
contraction. Under physiological conditions, most of the lanthanides are stable in the trivalent 
Ln3+ form, except Ce and Eu which can also exist as Ce4+ and Eu2+. The lanthanide elements 
have a similar ionic radius to calcium but differ in charge [46].  
Research on lanthanide coordination chemistry reveals that lanthanide aqua ions, i.e.  
[Ln(H2O)n]
3+, have coordination numbers of 9 from La to Eu whereas 8 ligands are observed 
for the series Dy to Lu. It is these features, i.e. high coordination numbers and similar size to 
calcium that sparks interest for research in the area of therapy and bioinorganic chemistry [73].   
A few of the lanthanide radio-active isotopes possess radiation properties that are feasible for 
radio-pharmaceutical use (see Figure III-1) and their coordination compounds are well-known 
in cancer research, not only due to their nuclear decay parameter (such as the type and energy 
of the particles emitted), but also half-life decay products of the radionuclides [50]. Radio-
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lanthanides that decay by beta particle emission have been explored for bone therapy and pain 
palliation as they emit a wide range of beta energies and half-life. In particular, Sm, Ho and Lu 
have desirable radiation properties for use in bone cancer [45]. 
 
Figure III-1:  Periodic table to show elements useful for internal radiodiagnosis and 
radiotherapy [74]. 
The present study has focussed on the element samarium and studied its coordination behaviour 
with the two novel water-soluble compounds based on 5-(diethoxy) phosphinylmethyl-8-
quinolinoxy (Scheme III-2). It is believed that the phosphinyl moieties will enable water-
solubility of the complexes as the first requirement, which is important because of the intention 
to target to bone cancer sites. To further enhance the above features, an addition 
bisphosphonate (1-aminoethane-1,1-diyl diphosphonic acid see Scheme III-1) has been 
prepared and coordinated to the Sm center to provide four complexes. In this chapter their 
synthesis and characterization using techniques such as 1H, 13C{1H} and 31P{1H} NMR, FT-
IR, CHN elemental, UV-Visible absorption spectra, TGA and HRMS are discussed. 
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3.3. Experimental. 
Samarium nitrate hexahydrate was obtained commercially (Sigma-Aldrich) and used without 
further purification. CH3CN, H3PO3 and PCl3 were all AR grade, and were obtained from 
Rochelle chemicals. Detailed synthetic procedures and data/spectra are listed in Appendices A 
to F. 
 
3.3.1. Synthesis of 1-aminoethane-1,1-diyl diphosphonic acid. 
The preparation of 1-aminoethane-1,1-diyl bisphosphonic acid was achieved under inert 
conditions at room temperature by the exothermic reaction of phosphorous trichloride (2 eq.) 
with acetonitrile (1 eq.) and phosphorous acid (3 eq.), resulting in spontaneous heating to ca. 
50 °C. The mixture was kept overnight and quenched with H2O, causing hydrolysis. The white 
precipitate obtained was filtered and washed with methanol to obtain the product. 
 
 
Scheme III-1: Synthetic procedure of 6. 
The 1H, 13C and 31P NMR spectra of compound (6) were obtained in D2O. The 
1H NMR 
spectrum showed a characteristic triplet at 1.47 pm integrating for 3 protons, representing the 
methyl group. The triplet arises due to equivalent coupling between the H atoms and the two P 
atoms. The 13C{H} NMR spectrum presents a triplet at 53.5 ppm due to C-P2 coupling, while 
the 31P NMR was characterized by a single signal at 13.20 ppm for the two equivalent 
phosphorus centers. ESI-TOF-HRMS gave (m/z): calculated for C2H9NO6P2 [M-H
+]: 
203.9832, found 203.9820, which accurately represents the anticipated molecular formula. 
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3.3.2. Complexation Methodology. 
The synthetic route to yield the four new samarium complexes is shown in Scheme III-2. Two 
of the complexes contain phosphinylmethyl-8-quinolinoxy phosphine oxide derivatives (7 and 
8), while the other two contain additionally the 1-aminoethane-1,1-diyl disphosphonic acid (8 
and 10). All the ligands were mixed in stoichiometric amounts with the samarium salt in 
acetonitrile at 50 °C.  
 
 
Scheme III-2: synthesis procedure for the coordination of the ligands to the samarium. 
Several attempts to grow crystals for single crystal X-ray data analysis were unsuccessful, and 
therefore made absolute establishment of the lanthanide coordination environment difficult. 
The composition of the complexes was studied using CHN elemental analysis, FTIR, and 
HRMS, and from this reasonable structure can be proposed.  
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3.4. Results and discussions. 
The characteristic signals observed in the 31P NMR spectra of the complexes exhibit significant 
up-field shifts from the ligand starting material. The results are summarized in Table III-1.  
Table III-1 compares the 31P NMR spectra of the ligands to those of the complexes. For ligand 
5 the data indicate that the coordination of Sm is with the P=O at position 8 of the quinoline  
as seen from the significant shifts from 23.47 ppm to ca. 12 ppm in the 31P NMR spectra for 
complexes 8 and 10. For complex 10 it can also be ascertained that the bisphosphonate 
coordinated as the phosphorus peak at 13.20 ppm for the free ligand shifted to 3.32 ppm. The 
31P NMR values for P=O in position 5 remains essentially the same and is indicative of non-
coordination of Sm at this site. 
Table III-1: 31P NMR of the ligands 5 and 6 and their metals complexes. 
Compound 
31P NMR in D2O 
5-P=O 8-P=O BP 
(5) 28.51 23.47 - 
(6) - - 13.20 
(8) 28.37 12.88  
(10) 28.17 12.32 3.32 
A comparison of some of the IR absorption bands of the complexes with those from their 
corresponding free ligands assisted with the elucidation of the coordination mode. These are 
presented in the Table III-2.  
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Table III-2: Selected IR bands comparison between compounds (4-6) and their samarium 
complexes (7-10). 
Compound ν(P=O) ν (C=N) ν OH, 
P(O)OH 
ν(Sm-N)                      ν (NO3-) 
ν1 ν4 ν2 ν3 Δν=ν1-
ν4 
(4) 1219 1589 - - - - - - - 
(5) 1174 1585 - -  - - - - 
(6) 1214 - 2754 - - - - - - 
(7) 1192 1561 - 409 1476 1304 1029 821 172 
(8) 1129 1563 - 406 1522 1323 1018 810 199 
(9) 1170 1577 528 413 1501 1304 1002 825 197 
      (10) 1148 1545 554 411 1508 1307 1037 802 201 
In general, the complexation induces a broadening of these bands associated with bathochromic 
shifts, as would be expected by coordination of N, and P=O functionalities to the Sm centre. 
The vibration frequency ν(P=O) was 1192 cm–1 and 1129 cm-1, respectively, for complexes 7 and 
8. In the free ligands, the corresponding frequencies for the free ligands 4 and 5 were observed 
at 1219 and 1174 cm–1, respectively. These data strongly support the notion of coordination via 
phosphoryl oxygen-frequency. The shifts of this magnitude are in agreement with analogous 
findings in the [74-77]. The corresponding bands for 9 and 10 were too intricate to elucidate. 
The vibration frequency ν(C=N) of the pyridine ring of quinoline observed at 1589 and 1585 in 
free ligands 4 and 5, respectively, band towards lower frequency about 29–12 cm–1 in their 
metal complexes. However, in all four complexes ν(Sm-N) bands were detected, confirming 
complexation to the quinolinyc N-donor site. The presence of new spectrum bands in the 
complexes at ca. 400 cm-1 may be due to the ν(Sm-N) mode in the new complexes, and similar 
observations have been reported [78-80]. Furthermore, the bonding mode of nitrate ligands 
could be confirmed by the splitting between the two highest frequency bands assigned to the 
NO3
- vibration, i.e. Δν = 172, 182, 197, 201 respectively for 7, 8, 9 and 10, and are consistent 
with the chelating bidentate mode of coordination with approximate C2ν symmetry [74,76].  
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Figure III-2: Superimposed FTIR spectra of (4) and (7). 
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Figure III-3: Superimposed FTIR spectra of (5) and (8). 
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To further confirm the structures of the prepared complexes CHN elemental analysis (Table 
III.3) and HRMS (Table III.4) were also conducted. These results show values that are 
consistent with proposed complexes where ligands and metal are present in equal 
stoichiometric quantities, representing a 1:1 Sm-ligand complex. In each case, the structures 
suggested in the Scheme III-2 are supported by the analytical data found in the appendices 
Table III-3: Summary of the CHN elemental analysis data for the complexes. 
Compounds code C (%) 
Calc. (Observed) 
H (%) 
Calc. (Observed) 
N (%) 
Calc. (Observed) 
7 27.51 (26.90) 3.72 (3.89)  7.13 (6.97) 
8 34.55 (33.64) 3.90 (3.97) 6.20 (5.85) 
9 24.24 (22.92) 3.87 (3.91) 7.07 (7.00) 
10 33.27 (31.27) 3.99 (3.63)  5.54 (4.91) 
The HRMS data for the complexes are summarized in the Table 3.4. 
Table III-4: HRMS (TOF MS ES+) predicted structures of the ligands and their complexes. 
Compounds code [M+H] + 
Calculated 
[M+H]+ 
Observed 
Predicted structure 
7 785.0206 785.3030 C18H27NO7P2Sm (NO3)3.(H2O) 
8 828.0083 828.0803 C26H27NO5P2Sm(NO3)3 
9 993.0178 993.2227 C18H27NO7P2Sm(NO3)3.(H2O). C2H9NO6P2 
10 1013.0202 1013.2632 C26H27NO5P2Sm(NO3)2.(H2O)2.C2H9NO6P2 
UV-visible absorbance spectral properties were also used to examine the formation of the 
complexes. The physical properties of 8-hydroxyquinoline derivative has been extensively 
studied [81], and their absorption spectra are characterized by a very intense band around the 
250 nm region, which is attributed to π-π* transitions. Figures III-4 and III-5 show the 
absorption spectra of the ligands (4) and (5) and their metal complexes, respectively, obtained 
in water. 
While comparing the absorption spectra of each ligand, to those of their complexes 
respectively, it can be observed that all complexes show red shifts of the absorption maximum, 
indicative of the interaction of the metal ion with the nitrogen of quinoline and is consistent 
with other related complexes where similar observations have been reported [82, 83]. 
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Figure III-4: UV-Visible absorption spectra of the free ligand (4) and the samarium 
complexes (7) and (9) in water. 
 
Figure III-5: UV-Visible absorption spectra of the free ligand (5) and the samarium 
complexes (8) and (10) in water. 
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To explore the thermal stability of the synthesized compounds, thermal analyses were carried 
out on all the complexes.  The TGA data are presented in the thermograms in Figures E1-E4 
(in the appendix E). These data suggest that, in general there are two endotherms and exotherms 
in the trace at 220-250 °C and 400-425 °C respectively. The first two likely correspond to loss 
of water (non-coordinated and coordinated), followed by decomposition of the ligands, the 
nitrate anions and decomposition of Sm to Sm2O3. 
3.5. Conclusion. 
Four novel Sm complexes with combinations of phosphinylmethyl-8-quinolinoxy 
phosphineoxide derivatives and 1-aminoethane-1,1-diyl disphosphonic acid were prepared, all 
of which were water-soluble. The complexes failed to yield crystals suitable for single crystal 
X-ray crystallography for unambiguous structure confirmation. Instead, several 
characterization techniques were employed to elucidate the structures presented. In each case, 
the structures suggested in Scheme III-2 are supported by analytical data found in the 
appendices. In summary, 31P NMR and FT-IR analysis support the notion of the coordination 
of the ligand to the Sm center through phosphine oxide and the nitrogen of the quinoline 
moiety. CHN elemental analysis and HRMS established a molecular formula indicative of 
stoichiometric ratios between Sm and phosphorus containing ligands. All complexes show red 
shifts of the absorption maximum in their UV-Vis spectra compared to the ligands. Thermal 
analysis reveal that complexes should be stable to well above physiological temperature.  
The next chapter will detail the biological activities, and hydroxyapatite interaction of 
samarium complexes. 
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CHAPTER IV: BIOLOGICAL ACTIVITIES AND HYDROXY-APATITE 
INTERACTION OF NOVEL DIETHOXYPHOSPHORYL 
METHYL QUINOLINOXY BASED LIGANDS AND 
THEIR SAMARIUM COMPLEXES.  
4.1. Chapter outline. 
This chapter provides background on bisphosphonate as a potential key substituent for the 
development of drugs that target metastasis in bone. The ligands and its samarium complexes, 
prepared in chapter 2 and 3, are preliminary evaluated for toxicity in the presence of HT-29 
cells before evaluation for bone adsorption employing hydroxyapatite as model. 
4.2. Introduction. 
The affinity of lanthanides for bone can be attributed to their similar chemical and biological 
properties of that of calcium. This similarity allows Ln3+ ions to exchange with calcium in bone 
tissue and affects the bone remodelling cycle by modulating osteoblast, the cells responsible 
for bone formation. The lanthanide ions can also have an inhibitory effect on osteoclast, the 
cells responsible for bone resorption [25,46]. What makes the lanthanides even more suitable 
are their radionuclides with nuclear decay parameters suitable for bone therapy application. 
However, in order for these lanthanides ions to have efficacy in the treatment of bone cancer, 
they must be delivered to bone. It is well known that the incorporation of a bisphosphonate 
functional group into the design of radiopharmaceuticals assist the drug to target bone. 
Chelators containing bisphosphonate groups (BPs) complexed to radiolanthanides have already 
proven their efficacy as bone targeting agents [28,51]. The main considerations in the design 
of BP based drugs is the relative affinity for bone mineral, and the inhibitory effect on cellular 
mechanisms responsible for bone resorption [30]. These aspects are fulfilled by different parts 
of the BP molecules and early studies suggested that they did not necessarily depend on each 
other. The P–C–P backbone allows the introduction of numerous R1 and R2 substituents that 
led to the synthesis of several pharmaceutical compounds with different properties (Figure IV-
1) [84].  
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Figure IV-1: Chemical structure of the bisphosphonates derivatives [85]. 
BPs display a strong affinity for binding to the bone hydroxyapatite (HAP), Ca5(PO4)3OH, 
Ca/P=1.66), [26].  This ability of the BPs to bind to HAP is increased when R1=OH (Figure 
IV-1). However, in vivo and in vitro studies have shown that such binding to bone prevents 
both crystal growth and HAP dissolution or breakdown similarly to what have been observed 
for pyrophosphates [85]. The high affinity of bisphosphonates towards bone is based on their 
ability to become incorporated into the hydroxyapatite crystal by chemisorption on to the 
surface of bone and the chelation to Ca2+ ions through the deprotonated oxygen atoms of the 
phosphonate unit in a bidentate coordination mode (Figure IV-2) [31]. The surface structure of 
the HAP also plays a significant role, and may result in either weak or strong binding of the 
phosphonate depending on the number of complementary binding sites between the two 
entities, either through hydrogen bonding from the phosphate itself or from additional 
functionalities grafted onto the phosphonate carbon backbone (Figure IV-2) 
 
Figure IV-2: Schematic representation for different mode of BP binding to hydroxyapatite 
crystal surface, adapted from [43]. 
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In (1) bidentate binding involving the two phosphonates, (2) tridentate binding from the R1 
side group (OH), and (3) additional interactions from a nitrogen containing R2 side group (e.g., 
alendronate). To summarize, the crystal structure of bone mineral surface hydroxyapatite 
Ca5(PO4)3OH, and the bisphosphonate molecular structure, strongly affect their chemical 
binding affinity [43].  
 
In this study we have prepared two novel phosphinyl-phosphine 8-quinolinoxy derivatives and 
a bisphosphonate. These 8-quinolinoxy derivatives have then been complexed to samarium, 
with and without the bisphosphonate (see Chapters 2&3). In this chapter these compounds have 
been preliminary assessed for their toxicity in presence of HT-29 colon cancer cells. Thereafter 
a preliminary evaluation of their effectiveness for bone pain palliation using HAP was 
conducted. 
4.3. Experimental methodology 
4.3.1. Materials.  
Water used in this study was purified by a full spectrum UV to control bacterial levels. All 
ligands and metal complexes discussed in this chapter were synthesized according to the 
procedures outlined in Chapter 2 and 3 of this dissertation. Chemical solvents were obtained 
commercially (Sigma-Aldrich) and used as received. The solvents toluene, acetonitrile, diethyl 
ether, ethanol, methanol, hexane was obtained from Rochelle chemicals and of analytical 
reagent grade. HAP powder was obtained commercially from Sigma-Aldrich. 
4.3.2. Cytotoxicity and adsorption techniques. 
To study the potential toxicity of the compounds, HT-29 colon adenocarcinoma cells (ATCC®: 
HTB-38TM) were used. These were cultured in DMEM (13.53 g.L–1) / NaHCO3 (3.7 g.L
–1) 
supplemented with 10% foetal calf serum (heat inactivated at 56 °C for 20 min), and antibiotics 
(1% Penicillin / Streptomycin / Fungizone Cocktail and 0.2% Gentamycin sulfate). Populations 
were incubated at 37 °C, in 5% CO2 sterile humidity (Jounan IGO 150 CELLlife™ Universal 
CO2 Incubator) and cultured every 2–3 days. Experimentation made use of culture passages 3–
7 from frozen stock. 
Populations of cells 105 cells.mL–1 were incubated with the ligands and their metal complexes 
at different concentrations (10, 50, 100 µM in dH2O) for 24 h. Cytotoxicity was analysed using 
the alamarBlue™ dye Reduction Assay (AbD Serotech, Germany). Treated cells were 
incubated with 10% v/v oxidised alamarBlue™ dye for 2 h in the dark (37 °C, 5% CO2). 
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Resulting dye fluorescence (Excitation: 544 nm and Emission: 590 nm) was quantified against 
maximal reduction induced via autoclaving 10% dye solution in culture media. Background 
fluorescence was normalised via subtraction of a culture media-alamarBlue™ dye solution 
(negative control). Detection made use of the BioTek Synergy HT multiplate reader with Gen5 
software. Comparative analyses were made between treated, vehicle control treated and 
untreated cell populations. 
For the adsorption study, inductively coupled plasma - optical emission spectrometry (ICP-
OES) was used to detect concentrations of phosphorus, samarium and calcium. Calibration 
curves were constructed using respective standards (1000 µg/mL in 2% HNO3). The specific 
surface area of HAP was determined according to BET method using the Tristar 3000 surface 
area analyser (average surface area = 14.68 m2/g).  
 
4.4. Results and discussion. 
4.4.1. Solubility test. 
All compounds were evaluated for their solubility prior to biological and adsorption studies. 
The solubility tests performed on all the ligands and their metals complexes showed an 
insolubility in diethyl ether and hexane. All the complexes are insoluble in THF and acetonitrile 
while the ligands show solubility. Except for ligand 6, the other ligands and all the complexes 
are soluble in methanol, ethanol and chloroform.  A high solubility of the all these compounds 
was observed in water. A summary of the solubility tests is presented in Table IV-1. 
Table IV-1. Solubility test of all compound ligands and complexes prepared in this study. 
I= insoluble, sl= slightly soluble, s= soluble, hs= high solubility 
Compound Diethyl ether C6H14 THF Acetone CH3CN CH3OH C2H5OH CHCl3 H2O 
4 I I s sl s s s s hs 
5 I I s sl s s s s hs 
6 i i sl sl sl i i i hs 
7 I I i sl I s s s hs 
8 I I i sl I s s s hs 
9 I I i sl I s s s hs 
10 I I i sl i s s s hs 
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4.4.2. Cytotoxicity study 
To study the toxicity of the compounds synthesized, HT-29 colon cancer cells (2x 105 
cells/mL1)  were incubated with different concentrations (10, 50, 100 µM) of compounds 4 to 
10 for 24 h.    Comparative analyses were made between treated, vehicle control treated and 
untreated cell populations.  Presented in Figures IV-3 and IV-4 are results for the highest 
concentration (100 µM) of the studied compounds. The results show that all compounds 
exhibited an insignificant toxicity effect, with an increase in cell viability as complexation is 
introduced.  The cells-maintained  viability of above 85%, which is acceptable for these studies. 
Remarkably, the cells even show a growth increase with the introduction of BP to the Sm 
coordination sphere. This is especially useful when considering complexes of this type for their 
potential in therapeutics.   In a similar study Dhumwad et al. described significant toxicity of 
samarium complexed quinoline derivatives on Hela cells [79]. 
In general, It can be concluded that the viability of HT-29 cells was not significantly affected 
by any of the compounds here, and implies that the precursors, ligands and their Sm complexes 
may be suitable candidates for the development of bone-targeting drug that present no adverse 
effect on health tissue. 
 
  
Figure IV-3: In vitro cell viability test of HT-29 cells untreated (U), compared to a vehicle control 
(water), compounds (4 and 6) and their samarium complexes (7 and 9) at increasing conditions (10-
100 µM). Statistical bars represent SEM (n=5).  
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Figure IV-4: In vitro cell viability test of HT-29 cells untreated (U), compared to a vehicle control 
(water), compounds (5 and 6) and their samarium complexes (8 and 10) at increasing conditions (10-
100 µM). Statistical bars represent SEM (n=5). 
 
 
4.4.3. Hydroxyapatite binding assay. 
In order to preliminary evaluate the prepared complexes’ ability to interact and adsorb onto 
bone material, a brief study was conducted using HAP as a model for bone. The general 
methodology for the adsorption study to HAP is as follow: The complexes were weighed and 
dissolved in a volumetric flask using distilled water to provide known concentrations of Sm in 
the studied complex. Samples were analysed for concentrations of Sm, P and Ca with ICP-OES 
before contact with HAP. The concentrations for Ca was taken as zero as it was below the 
detection level of the instrument. Each prepared concentration (ca. 1 mL) was then mixed with 
hydroxyapatite powder (ca. 250 mg) in a 2 mL falcon tube. The resulting suspensions were 
agitated at room temperature for 24h using a rotary carousel.  The HAP suspension was then 
centrifuged at 22500 rpm and the aliquots of the supernatant were diluted and analysed for 
concentrations of Sm, P and Ca with ICP-OES. Illustrated below (Figures IV-5 and 6) are 
graphs of samples 7 and 8 grouped, 9 and 10 grouped.  
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Figure IV-5: Comparison of the concentration of Sm, Ca and P in 7 and 8 before and after contact 
with HAP. 
 
Figure IV-6: Comparison of the concentration of Sm, Ca and P in 9 and 10 before and after 
interaction with HAP. 
The results show that Sm was completely removed from solution beyond the detection level of 
the instrument and implies that Sm was adsorbed into the HAP matrix. For all complexes Ca 
was released after exposure to the complexes, but with more significant amounts for 7 and 8. 
The levels of P remains stable in 7 and 8, which may indicate non-adsorption of these ligands 
into the HAP matrix. For compounds 9 and 10 the P levels show that half of the concentration 
of P in either 9 and 10 remained in solution. This may suggest decomposition of these 
complexes with only Sm coordinated to bisphosphonate (Sm-6) entering HPA matrix. 
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4.5. Conclusion 
Solubility tests show that the compounds are soluble in most common solvents to varying 
extent, with water being the best option. All compounds were therefore viable for further 
testing as potential candidates for drug development. Preliminary testing with HT-29 colon 
cells showed all compounds had limited toxicity effects on healthy cells, and thus further 
contribute to their feasibility as potential drugs. Finally, the adsorption of the Sm compounds 
into the HAP matrix also seems feasible from the preliminary adsorption study conducted.     
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CHAPTER V: GENERAL CONCLUSION. 
This research discussed the synthesis of two novel water-soluble ligands 5-((diethoxy 
phosphinyl) methyl) quinolin-8yl diethyl phosphate and 5-((diethoxy phosphinyl) methyl) 
quinoline-8yl diphenyl-phosphinate starting with the phosphorylation of quinoline and 
thereafter the attachment of phosphine derivatives to prepare the two ligands. These ligands 
were fully characterised by 1H NMR, CHN elemental analysis, 31P NMR, FTIR, HRMS. A 
single crystal structure analysis could only be obtained for the precursor. Although the 
oxidation of the second phosphorus center was not initially anticipated, complexation with 
samarium was nonetheless pursued as coordination through the oxygen of the P=O could be 
still be viable for the hard Lewis acid metal.  
Complexation of the two ligands with samarium nitrate yielded four novel complexes. The FT-
IR, NMR, CHN-elemental analysis, HRMS and UV-Vis support the formation of the 
complexes. In the case of 5-((diethoxy phosphinyl) methyl) quinoline-8yl diphenyl-
phosphinate results were conclusive of coordination through the second phosphorus P=O and 
N atoms. However, for the case of 5-((diethoxy phosphinyl) methyl) quinolin-8yl diethyl 
phosphate the NMR results were not conclusive for such coordination, and it could only be 
confirmed with additional analysis that the ligand is indeed attached.  Several attempts were 
made to grow crystals of the complexes using several techniques but were unsuccessful. 
 
The ligands and their samarium complexes were tested for toxicity using HT-29 colon cells.  
The result shown insignificant toxicity to the cell viability with complexes behaving the best.  
All the complexes were evaluated with preliminary testing of adsorption on HAP, from which 
it was observed that samarium was completely adsorbed from the solution, with the release of 
calcium from HAP into the supernatant. 
 
Future work  
In summary this work shows that it is possible to construct new water-soluble systems based 
on quinoline-phosphine derivatives and preliminary testing indicates a window of opportunity 
for further medical application research. The in vitro evaluation needs to be expanded to more 
detailed toxicity and adsorption studies. In addition, competition studies with physiological 
minerals (Na, K, Zn, etc.) and the chelation to radio-active Sm (at the facilities of NECSA) will 
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further evaluate the binding affinity of chelator and metal. Finally, the work can also be 
expanded to other metals with desirable characteristics in radiopharmaceuticals.   
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APPENDICES 
A. Experimental procedure 
A1. Synthesis of 5-chloromethyl-8-hydroxyquinoline (2). 
A mixture of 8-hydroxyquinoline (5.0 g, 34.21 mmol), HCl (5.5 mL, 32% v/v) and formaldehyde 
(5.5 mL, 37% v/v) was treated with HCl gas (generated with equal amount of HCl and H2SO4) under 
stirring for 6h. After letting the mixture stand for 2h a yellow solid was obtained and washed with 
conc. HCl and then dried under vacuum to afford the product as a yellow solid. 
Yield: 3.14 g, 63.4% 
1H NMR (400 MHz, D2O): δ 9.09(d, J = 8.7 Hz, 1H), 8.83 (d, J =5.3 Hz, 1H), 7.92 (dd, J = 8.6, 5.4 
Hz, 1H), 7.56 (d, J = 8.0 Hz, 1H), 7.22 (d, J =8.0 Hz, 1H), 4.89 (s, 2H) 
E.A (%): Anal. Calc. for C10H9Cl2NO: C, 52.20; H, 3.94; N, 6.09. Found C, 51.75; H, 3.8; N, 6.06. 
IR (KBr, cm-1): 2988 ν(C-H aromatic), 1598 ν(C=C aromatic), 1488 ν(CH2Cl), 1336 ν(OH). 
 
 
A2. Synthesis of 5-(diethoxy) phosphinylmethyl-8-hydroxyquinoline (3). 
Triethyl phosphite (4.6 mL, 4.45 g, 27 mmol) and (1) (2.05 g, 9 mmol) were combined and stirred 
at 110 °C for 24 h. Unreacted triethyl phosphite was removed under vacuum and the pale-yellow 
residue obtained was triturated with DEE to afford pure pale-yellow product. 
Yield: 3.49 g, 53.7% 
δ 8.64 (d, J = 4.1 Hz, 1H), 8.34 (d, J =8.6 Hz, 1H), 7.47 (dd, J = 8.6, 4.2 Hz, 1H), 7.25 (dd, J = 7.9, 
3.9 Hz, 1H), 6.99 (d, J =7.9 Hz, 1H), 3.83 (q, J = 6.7, 4 H), 3.51 (d, J =21.0 Hz, 2H), 0.98 (t, J = 7.1 
Hz, 6 H). 
31P {1H} NMR (162 MHz, D2O): δ 29.37 (s, 1P). 
IR (KBr, cm-1): 2994 ν(C-H, aromatic), 1592 ν(C=C), 1236 ν(P=O), 1026 ν(P-O-). 
E.A (%): Anal. Calc. for C14H18NO4P: C, 56.95; H, 6.14; N, 4.74. Found: C, 56.69; H, 5.90; N, 4.55. 
ESI-TOF-HRMS (m/z): calculated for C14H19NO4P [M+H+]: 296.1046, found 296.1051. 
 
 
A3. Synthesis of 5-(diethoxy) phosphonylmethyl-8-quinolinoxy diethyl phosphate (4). 
(3) (0.128 g, 0.434 mmol, 1 equiv.) was dissolved in toluene (5 mL) and triethylamine (0.09 mL, 
0.65 mmol, 0.066 g, 1.5 equiv.) was added under nitrogen atmosphere. The reaction mixture was 
stirred for 15 min at room temperature and then cooled to 0 °C in an ice bath. Diethyl chlorophosphite 
(0.068 g, 0.434 mmol, 1 equiv.) was added dropwise to the solution with stirring. The resulting 
solution was warmed to room temperature and stirred overnight. The mixture was filtered using a 
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syringe filter to remove the triethylamine chloride salt. The filtrate was evaporated to dryness under 
vacuum and a yellow oil was obtained. 
Yield: 0.194 g, 74%.  
1H NMR (400 MHz, D2O): δ 8.63 (d, J =3.7 Hz, 1H), 8.20 (d, J =8.6 Hz, 1H), 7.39 (dd, J = 8.4, 4.1 
Hz, 1H), 7.31 (d, J = 7.9 Hz, 1H), 7.18 (dd, J =7.6, 3.3 Hz, 1H), 4.06 (q, J= 7.4 Hz, 4H), 3.74 (q, J 
=7.0 Hz, 4H ), 3.38 (d, J =21.8 Hz, 2H), 1.06 (t, J = 7.1 Hz, 6H), 0.99 (t, J = 7.0 Hz, 6 H); 
 31P {1H} NMR (162 MHz, D2O): δ 27.63 (s, 1P), -5.65 (s, 1P);  
13C NMR (101 MHz, D2O): δ 149.85 , 144.1, 144.0, 138.4, 134.9, 128.7, 127.9 , 125.6, 122.2, 118.8. 
66.3, 63.6, 28.3, 15.3, 15.2 
 
IR (KBr, cm-1): 1589 ν(C=N), 1219 ν(P=O), 1018 
E.A(%): Anal. Calc. for C18H27NO7P2:  C, 50.12; H, 6.31; N, 3.25, Found: C, 49.68; H, 6.13; N, 3.59. 
ESI-TOF-HRMS (m/z): calculated for C18H28NO7P2 [M+H+]: 432.1336, found 432.1341. 
 
 
A4. Synthesis of 5-(diethoxy) phosphonyl methyl -8-quinolinoxy diphenyl phosphonyl (5). 
(3) (0.125 g, 0.424 mmol, 1 equiv.) was dissolved in toluene (5 mL) and triethylamine (0.09 mL, 
0.635 mmol, 0.064 g, 1.5 equiv.) was added under nitrogen atmosphere. The reaction mixture was 
stirred for 15 min at room temperature and cooled to 0 °C in an ice bath. Chlorodiphenylphosphine 
(0.093 g, 0.424 mmol, 1 equiv.) was added dropwise to the solution with stirring. The resulting 
solution was warmed to room temperature and stirred overnight. The mixture was filtered using a 
syringe filter to remove the triethylamine hydrochloride salt. The filtrate was evaporated to dryness 
under vacuum and a yellow oil was obtained. 
Yield: 0.189 g, 67%       
1H NMR (400 MHz, D2O): δ 8.80 (d, J = 8.7 Hz, 1H), 8.72 (d, J = 5.04 Hz, 1H), 7.77-7.73(m, 1H, ), 
7.51-7.46 (m, 4H), 7.39 (dd, J = 8.0, 3.8 Hz, 1H), 7.27-7.20 (m, 6H), 7.14 (d, J = 8.0 Hz, 1H), 3.85 
(q, J= 7.4 Hz, 4H), 3.53 (d, J = 21.31 Hz, 2H, 0.99 (t, J = 7.0 Hz, 6H).  
31P {1H} NMR (162 MHz, D2O): δ 28.12 (s, 1P), 23.35 (s, 1P).  
13C  NMR (101 MHz, D2O): δ 147.4, 143.3, 142.5, 137, 136.4, 132.3, 131.1, 130.7, 130.5, 128.2 
121.5, 119.3, 115.3, 63.8, 27.8, 15.4  
IR (KBr, cm-1):  2973 ν(C-H aromatic),1585 ν(C=N), 1174 ν(P=O), 
E.A(%): Anal. Calc. for C26H27NO5P2: C, 63.03; H, 5.49, N,2.83. found: C, 62.25; H, 5.28, N, 2.41. 
ESI-TOF-HRMS (m/z): calculated for C26H28NO5P2 [M+H+]: 496.1437, found 496.1437. 
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A5. Synthesis of 1-aminoethane-1,1-diyl) bis-phosphonic acid (6). 
To a mixture of acetonitrile (4.5 mL, 1 equiv.) and phosphorous acid (21.25 g, 3 equiv.) in two-
necked round bottom flask was vigorously stirred at room temperatures under nitrogen was added 
dropwise (14.8 mL) of phosphorous trichloride. An exothermic reaction occurred causing the 
temperature to rise to ca. 50 oC, and was maintained at this temperature overnight through additional 
heating. The reaction mixture was quenched carefully with 15 mL of H2O under vigorous stirring, 
resulting in a temperature rise to 90 oC. Stirring was stopped after 2 h, the white precipitate obtained 
from hydrolysis was filtered off and wash with several portions of dry methanol to obtain the 
compound 6. 
Yield: 29.3 g, 59% 
1H NMR (400 MHz, D2O): δ = 1.49 (t, 3J P-H= 5.7 Hz, 3H) 
31P {1H} NMR (162 MHz, D2O): δ 13.20 ppm 
13C NMR, (101 MHz, D2O): δ 53.5 (t, 1J P-C= 151.2, Hz, C-P2), 17.4 ppm                        
E.A (%): Anal. Calc. for C2H9NO6P2: C, 11.72; H, 4.42; N, 6.83 found: C, 11.27; H, 4.67, N, 6.72. 
ESI-TOF-HRMS (m/z): calculated for C2H9NO6P2 [M-H+]: 203.9832, found 203.9820. 
 
A6. General procedure for the synthesis of the complexes (7) and (8). 
A solution of Sm(NO3)3.6H2O (1 eq.) in acetonitrile was added dropwise with stirring to a solution 
of corresponding ligand 4 or 5 (1 eq.) dissolved in acetonitrile. The resulting solution was stirred 
over night at 50 °C. The precipitate obtained was filtered off and washed with acetonitrile and dried 
under vacuum affording the complexes.   
(7) Yield: 0.325 g, 65%. 
31P {1H} NMR (162 MHz, D2O): δ 27.80; -5.62 
IR (KBr, cm-1):  1561 ν(C=N), 1192 ν(P=O), 409 ν(Sm-N). 
E.A (%): Anal. Calc. for C18H29N4O17P2Sm: C, 27.51; H, 3.72,   N, 7.13. found: C, 26.90; H, 3.89, 
N, 6.97. 
ESI-TOF-HRMS (m/z): calculated for [Sm(4)].(NO3)3.H2O [M+H+]: 785.0206, found 785.3030 
 
(8) Yield: 0.365 g, 63%. 
31P {1H} NMR (162 MHz, D2O): δ 28. 37; 12.88. 
IR (KBr, cm-1):  1533 ν(C=N), 1129 ν(P=O), 406 ν(Sm-N). 
EA (%): Anal. Calc. for C26H27NO5P2Sm(NO3)3: C, 34.55; H, 3.90; N, 6.20. found: C, 33.64; H, 
3.97; N, 5.85. 
ESI-TOF-HRMS (m/z): calculated for [Sm(5)].(NO3)3 [M+H+]: 828.0083, found 828.0803 
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A7. General procedure for the synthesis of the complexes (9) and (10). 
A solution of Sm(NO3)3.6H2O (1 eq.) in acetonitrile was added dropwise with stirring to a solution 
mixture of ligand 4 or 5 (1 eq.) dissolved in CH3CN and ligand 6 (1eq.) preliminary dissolved in 
H2O. The resulting mixture was stirred over night at 50°C. The precipitate obtained was filtered off 
and washed with CH3CN and dried under vacuum affording the analytical pure complexes. 
(9) Yield: 0.298 g, 66%. 
31P {1H} NMR (162 MHz, D2O): δ 27. 68; -5.23; 0.37. 
IR (KBr, cm-1):   528 ν(OH, P(O)POH); 413 ν(Sm-N). 
E.A(%): Anal. Calc. for C20H38N5O23P4Sm:      C, 24.24; H, 3.87; N, 7.07. found: C, 22.92; H, 3.91; 
N, 7.00. 
ESI-TOF-HRMS (m/z): calculated for [Sm(4)(6)].(NO3)3.H2O [M+H+]: 993.0178, found 993.2227 
 
(10) Yield: 0.327 g, 64%. 
31P {1H} NMR (162 MHz, D2O): δ 28.17; 12.32; 3.32. 
IR (KBr, cm-1):   644 ν(OH, P(O)POH); 411 ν(Sm-N). 
E.A (%): Anal. Calc. for C28H40N4O19P4Sm:      C, 33.27; H, 3.99; N, 5.54. found: C, 32.27; H, 
3.63; N, 4.91 
ESI-TOF-HRMS (m/z): calculated for [Sm(5)(6)].(NO3)2.(H2O)2 [M+H+]: 1013.0202, found 
1013.2632. 
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B. NMR Data 
 
 
B1.  1H NMR Spectrum of (2) in D2O. 
 
 
B2.  1H NMR Spectrum of (3) in D2O. 
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B3.  1H NMR Spectrum of (4) in D2O. 
 
 
 
B4. 1H NMR Spectrum of (5) in D2O 
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B5.  31P NMR Spectrum of (3) in D2O. 
 
B6.  31P NMR Spectrum of (4) in D2O. 
 
B7. 31P NMR Spectrum of (5) in D2O. 
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B8.13C NMR Spectrum of (4) in D2O. 
 
B9. 13C NMR Spectrum of (5) in D2O. 
 
 
 
62 
 
 
B10. 1H NMR Spectrum of (6) in D2O. 
 
B11. 31P NMR Spectrum of (6) in D2O. 
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. 
 
B12. 31P NMR Spectrum of (8) in D2O. 
 
B13. 31P NMR Spectrum of (10) in D2O. 
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B14. 31P NMR spectrum (7). 
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C. ESI-TOF-HRMS SPECTRUM DATA 
 
C1. ESI-TOF-HRMS Spectrum of (3). 
 
 
C2. ESI-TOF-HRMS Spectrum of (4) 
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C3. ESI-TOF-HRMS Spectrum of (5). 
 
 
C4. ESI-TOF-HRMS Spectrum of (6) 
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C5. ESI-TOF-HRMS Spectrum of (7). 
 
 
C6. ESI-TOF-HRMS Spectrum of (8). 
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C7. ESI-TOF-HRMS spectrum of (9). 
 
 
C8. ESI-TOF-HRMS spectrum of (10). 
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D. IR Data 
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D1. FT-IR Spectrum of (3). 
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D2. FTIR Spectrum of (6). 
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D3. FTIR Spectrum of (9). 
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D4. FTIR Spectrum of (10). 
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E. THERMAL STABILITY DATA 
 
E1. TGA spectrum of (7). 
 
E2. TGA Spectrum of (8). 
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E3. TGA Spectrum of (9). 
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E4. TGA Spectrum of (10). 
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F. UV-VISIBLE ABSORPTION  DATA 
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F1. UV-Visible absorption spectra of the 
free ligand (4) and the samarium complexes 
(7) and (9) in water. 
F2. UV-Visible absorption spectra of the 
free ligand (5) and the samarium complexes 
(8) and (10) in water. 
 
 
G. CALIBRATION CURVES 
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concentration(mg/L)
Equation y = a + b*x
Weight No Weighting
Residual Sum of 
Squares
0.51414
Pearson's r 0.99971
Adj. R-Square 0.99932
Value Standard Error
B Intercept 0.08986 0.15613
B Slope 0.30056 0.00297
R=0.99971
 
G1. Calibration curve for 
Ca (absorbance 
315,887). 
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Equation y = a + b*x
Weight No Weighting
Residual Sum 
of Squares
2.0017E-5
Pearson's r 0.99966
Adj. R-Square 0.9992
Value Standard Error
P213.628 Intercept 0.0013 9.74194E-4
P213.628 Slope 0.00174 1.85246E-5
R2=0.9992
 
G2. Calibration curve for 
Phosphorus (absorbance 
213.618). 
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Weight No Weighting
Residual Sum 
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0.00266
Pearson's r 0.99993
Adj. R-Square 0.99983
Value Standard Error
J Intercept 0.01658 0.01123
J Slope 0.04331 2.13552E-4
R2=0.9998
 
G3. Calibration curve for 
Samarium (absorbance 
428.079). 
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H. TABLE 
H.1. Crystal data and structure refinement for compound 3 
Identification code  3 
Empirical formula  C14 H18 N3 O2 P 
Formula weight  291.28 
Temperature  100(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  C 2/c 
Unit cell dimensions a = 11.142(17) Å = 90°. 
 b = 11.053(18) Å = 95.49(5)°. 
 c = 24.06(4) Å  = 90°. 
Volume 2949(8) Å3 
Z 8 
Density (calculated) 1.312 Mg/m3 
Absorption coefficient 0.192 mm-1 
F(000) 1232 
Theta range for data collection 1.701 to 28.589°. 
Index ranges -14<=h<=14, -14<=k<=14, -32<=l<=32 
Reflections collected 29599 
Independent reflections 3737 [R(int) = 0.1237] 
Completeness to theta = 25.242° 100.0 %  
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 3737 / 0 / 184 
Goodness-of-fit on F2 1.034 
Final R indices [I>2sigma(I)] R1 = 0.0823, wR2 = 0.2291 
R indices (all data) R1 = 0.1731, wR2 = 0.2826 
Extinction coefficient n/a 
Largest diff. peak and hole 0.411 and -0.251 e.Å-3 
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I. Toxicity data  
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